10/033,055

```
      (FILE 'HOME' ENTERED AT 09:40:34 ON 25 JUN 2004)

      FILE 'REGISTRY' ENTERED AT 09:40:55 ON 25 JUN 2004
L1              1 S (169590-42-5)/RN
L2              1 S (76-42-6)/RN

      FILE 'CAPLUS' ENTERED AT 09:41:40 ON 25 JUN 2004
L3             28 S L1 AND L2
L4            973 S L1
L5            732 S L2
L6            178 S L4 AND PAIN?
L7              8 S L6 AND SYNERG?
L8             56 S L4 AND (OPIOID? OR OPIATE? OR MORPHIN?)
L9             32 S L8 NOT L3
L10             8 S L1 AND PAIN? AND SYNERG?

      FILE 'MEDLINE, SCISEARCH, BIOSIS' ENTERED AT 09:47:31 ON 25 JUN 2004
L11          2083 S L1
L12             2 S L11 AND PAIN? AND SYNERG?
L13            89 S L11 AND PAIN? AND (ACETAMINOPHEN? OR IBUPROFEN? OR ASPIRIN?)
L14            69 DUP REM L13 (20 DUPLICATES REMOVED)

      FILE 'USPATFULL' ENTERED AT 09:50:44 ON 25 JUN 2004
L15           301 S L1
L16           221 S L15 AND (ASPIRIN? OR ACETAMIN? OR IBUPROFEN?)
L17           169 S L16 AND PAIN?
L18            58 S L17 AND (PAIN)/CLM
L19            23 S L18 AND SYNERG?

      FILE 'USPATFULL' ENTERED AT 09:54:25 ON 25 JUN 2004
L20            21 S L1 AND L2
L21          1480 S (COX?)/CLM
L22            54 S (OPIOID? OR OPIAT? OR MORPHIN? OR OXYCOD?)/CLM AND L21

      FILE 'WPIDS' ENTERED AT 09:57:47 ON 25 JUN 2004
L23             0 S L1

      FILE 'CAPLUS' ENTERED AT 09:58:04 ON 25 JUN 2004
L24           973 S L1
L25           178 S L24 AND PAIN?

      FILE 'STNGUIDE' ENTERED AT 09:59:42 ON 25 JUN 2004

      FILE 'CAPLUS' ENTERED AT 10:01:37 ON 25 JUN 2004

      FILE 'STNGUIDE' ENTERED AT 10:03:17 ON 25 JUN 2004

      FILE 'MEDLINE, SCISEARCH' ENTERED AT 10:04:01 ON 25 JUN 2004
L26           836 S L1
L27           155 S L26 AND PAIN?

=>
```

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **169590-42-5** REGISTRY
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
CN Celebrex
CN Celecoxib
CN Celocoxib
CN SC 58635
CN YM 177
FS 3D CONCORD
DR 184007-95-2, 194044-54-7
MF C17 H14 F3 N3 O2 S
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

962 REFERENCES IN FILE CA (1907 TO DATE)
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
973 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **76-42-6** REGISTRY
CN Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Codeinone, 7,8-dihydro-14-hydroxy- (6CI, 7CI)
CN Morphinan-6-one, 4,5α-epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI)
OTHER NAMES:
CN (-)-Oxycodone
CN 14-Hydroxydihydrocodeinone
CN 3-O-(Methyl)oxymorphone
CN 6-Oxo-14-hydroxy-7,8-dihydrocodeine
CN 7,8-Dihydro-14-hydroxycodeinone
CN Dihydro-14-hydroxycodeinone
CN Dihydrohydroxycodeinone
CN Dihydrone
CN NSC 19043
CN Oxanest
CN Oxicon
CN Oxycodeinone
CN Oxycodone
CN Oxymorphone 3-methyl ether
FS STEREOSEARCH
MF C18 H21 N O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study)

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

728 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
732 REFERENCES IN FILE CAPLUS (1907 TO DATE)
32 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>

L25 ANSWER 178 OF 178 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:231026 CAPLUS
DN 126:264035
TI Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
AU Penning, Thomas D.; Talley, John J.; Bertenshaw, Stephen R.; Carter, Jeffery S.; Collins, Paul W.; Docter, Stephen; Graneto, Matthew J.; Lee, Len F.; Malecha, James W.; Miyashiro, Julie M.; Rogers, Roland S.; Rogier, D. J.; Yu, Stella S.; Anderson, Gary D.; Burton, Earl G.; Cogburn, J. Nita; Gregory, Susan A.; Koboldt, Carol M.; Perkins, William E.; Seibert, Karen; Veenhuizen, Amy W.; Zhang, Yan Y.; Isakson, Peter C.
CS Departments of Chemistry Inflammatory Diseases Research and Molecular Pharmacology, Searle Research and Development, Skokie, IL, 60077, USA
SO Journal of Medicinal Chemistry (1997), 40(9), 1347-1365
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Sulfonamide-containing 1,5-diarylpyrazole derivs. were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compds. with acceptable pharmacokinetic profiles. This work led to the identification of SC-58635 (celecoxib, I), which is currently in phase III clin. trials for the treatment of rheumatoid arthritis and osteoarthritis.
IT **Pain**
(hyperalgesia; diarylpyrazoles as cyclooxygenase 2 inhibitors)
IT **169590-42-5P** 170569-50-3P 170569-69-4P 170569-75-2P
170569-83-2P 170569-85-4P 170569-88-7P 170569-91-2P 170570-25-9P
170570-80-6P 170570-81-7P 170571-00-3P 170571-05-8P 170571-29-6P
170571-71-8P 170571-92-3P 170571-97-8P 170572-00-6P 170572-05-1P
170572-08-4P 188816-97-9P 188816-98-0P 188816-99-1P 188817-00-7P
188817-07-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(diarylpyrazoles as cyclooxygenase 2 inhibitors)

L25 ANSWER 176 OF 178 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:521520 CAPLUS
DN 127:171270
TI Outcome of specific COX-2 inhibition in rheumatoid arthritis
AU Lipsky, Peter E.; Isakson, Peter C.
CS Rheumatic Diseases Division, Department of Internal Medicine, University Texas Southwestern Medical Center at Dallas, Dallas, TX, 75235-8884, USA
SO Journal of Rheumatology, Supplement (1997), 49(Progress toward a New Class of Therapeutics: Selective COX-2 Inhibition), 9-14
CODEN: JRSUDX; ISSN: 0380-0903
PB Journal of Rheumatology
DT Journal
LA English

=> d 176 ab

L25 ANSWER 176 OF 178 CAPLUS COPYRIGHT 2004 ACS on STN
AB We reviewed data suggesting the hypothesis that specific inhibition of the inducible isoform of cyclooxygenase, COX-2, would provide therapeutic benefit in patients with rheumatoid arthritis (RA) with less gastrointestinal toxicity and presented the results of a therapeutic trial to test this hypothesis. Various doses of the selective COX-2 inhibitor, celecoxib, or placebo were used to treat patients with RA in a 4 wk, double blind, placebo controlled trial. Celecoxib provided significant improvement in patient global assessment, morning stiffness, and the number of **painful** and tender joints compared with placebo. In addition, the number of withdrawals in celecoxib treated patients was significantly less than in the placebo group. No significant adverse events and no difference in the total number of adverse events were noted between the placebo and celecoxib groups. At the doses employed, celecoxib inhibited only COX-2 and not COX-1. Specific COX-2 inhibition with celecoxib causes significant improvement in the signs and symptoms of RA.

L27 ANSWER 155 OF 155 MEDLINE on STN
AN 97393128 MEDLINE
DN PubMed ID: 9249645
TI Outcome of specific COX-2 inhibition in rheumatoid arthritis.
AU Lipsky P E; Isakson P C
CS Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235-8884, USA.
SO Journal of rheumatology, (1997 Jul) 24 Suppl 49 9-14. Ref: 21
Journal code: 7501984. ISSN: 0315-162X.
CY Canada
DT (CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199709
ED Entered STN: 19970916
Last Updated on STN: 20000303
Entered Medline: 19970904

L27 ANSWER 154 OF 155 MEDLINE on STN
AN 97393130 MEDLINE
DN PubMed ID: 9249647
TI **Pain** management in osteoarthritis: the role of COX-2 inhibitors.
AU Lane N E
CS Department of Medicine, University of California at San Francisco 94143, USA.. nelane@itsa.ucsf.edu
NC AG05407 (NIA)
AR20684 (NIAMS)
SO Journal of rheumatology, (1997 Jul) 24 Suppl 49 20-4. Ref: 30
Journal code: 7501984. ISSN: 0315-162X.
CY Canada
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199709
ED Entered STN: 19970916
Last Updated on STN: 20000303
Entered Medline: 19970904

=>